INDO US BIOTECH LTD (INDOUS) financials

INDO US BIOTECH LTD (INDOUS) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 2004, Indo US Bio-Tech Ltd is engaged in production and processing of commercial and vegetable seeds[1]

Market Cap: ₹144Cr.
Current Price: ₹72.0
Stock P/E: 12.6
ROE: 15.3%
ROCE: 14.5%
Book Value: ₹46.2
Dividend Yield: 0.00%
52W High / Low: ₹159/70.0

In Jun 2026, INDO US BIOTECH LTD (INDOUS) reported sales ₹32.99 Cr and net profit ₹3.04 Cr.

Annual TTM: sales ₹113 Cr, net profit ₹11 Cr.

Shareholding: Promoters 68.29% (Sep 2026), FIIs 0.01% (Sep 2026), DIIs 0.25% (Sep 2026), Public 31.46% (Sep 2026), No. of Shareholders 4,629% (Sep 2026).

INDOUS quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	22.17	23.56	33.38	30.77	30.85	22.80	26.02	32.99
Expenses	17.05	18.02	28.80	25.30	26.69	18.65	22.79	29.02
Operating Profit	5.12	5.54	4.58	5.47	4.16	4.15	3.23	3.97
OPM %	23.09%	23.51%	13.72%	17.78%	13.48%	18.20%	12.41%	12.03%
Other Income	0.02	0.02	0.12	0.00	0.03	0.01	0.02	0.12
Interest	0.52	0.38	0.26	0.45	0.42	0.77	0.60	0.74
Depreciation	0.18	0.16	0.56	0.20	0.21	0.22	0.27	0.27
Profit before tax	4.44	5.02	3.88	4.82	3.56	3.17	2.38	3.08
Tax %	2.03%	-0.80%	4.90%	2.49%	3.09%	5.36%	17.23%	1.30%
Net Profit	4.36	5.05	3.68	4.70	3.45	3.00	1.97	3.04
EPS in Rs	2.17	2.52	1.84	2.34	1.72	1.50	0.98	1.52
Raw PDF	—	—	—	—	—	—	—	—

INDOUS profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	40	39	49	61	73	104	110	113
Expenses	36	34	42	51	62	85	93	97
Operating Profit	4	6	7	9	11	19	17	16
OPM %	10%	14%	14%	15%	15%	18%	15%	14%
Other Income	-0	0	0	0	0	0	0	0
Interest	1	1	1	1	2	1	2	3
Depreciation	0	0	0	1	1	1	1	1
Profit before tax	3	4	5	7	9	17	14	12
Tax %	12%	-23%	5%	2%	6%	2%	6%	—
Net Profit	3	5	5	7	8	16	13	11
EPS in Rs	1.74	3.52	2.86	3.60	4.11	8.11	6.54	5.72
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	—

INDOUS balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	5	6	6	9	10	20	20	20
Reserves	9	10	15	30	44	43	58	72
Borrowings	6	9	11	12	12	14	15	37
Other Liabilities	4	10	11	4	3	7	4	4
Total Liabilities	24	35	44	56	69	84	98	133
Fixed Assets	1	1	2	6	7	7	10	11
CWIP	1	1	2	2	1	4	0	0
Investments	0	0	0	0	0	0	0	0
Other Assets	21	32	39	48	61	74	88	121
Total Assets	24	35	44	56	69	84	98	133

INDOUS cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	-3	-1	0	3	1	2	1	-13
Cash from Investing Activity	-3	-1	-2	-5	-7	-3	-1	-2
Cash from Financing Activity	6	2	1	2	6	1	-1	20
Net Cash Flow	0	0	-0	-0	0	1	-1	6
Free Cash Flow	-4	-1	-2	-1	-1	-0	1	-15
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	-92%	-20%	6%	47%	9%	23%	9%	-71%

INDOUS shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	70.18%	70.18%	70.18%	70.18%	70.18%	68.29%	68.29%	68.29%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.18%	0.01%	0.01%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.25%
Public	29.82%	29.83%	29.83%	29.83%	29.83%	31.53%	31.70%	31.46%
No. of Shareholders	2,828	2,780	3,112	4,130	4,738	4,531	4,690	4,629

INDOUS key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	94	193	229	152	148	95	53	45
Inventory Days	176	751	—	—	—	—	—	—
Days Payable	34	667	—	—	—	—	—	—
Cash Conversion Cycle	236	276	229	152	148	95	53	45
Working Capital Days	129	137	186	257	285	266	247	248
ROCE %	20%	17%	18%	16%	15%	14%	21%	14%

INDOUSUpdated 18 Oct 2026, 13:03

Indo Us Biotech Ltd

INDOUSUpdated 18 Oct 2026, 13:03

Market Cap

₹144Cr.

Current Price

₹72.0

High / Low

₹159/70.0

Stock P/E

12.6

ROE15.3%

ROCE14.5%

Book Value₹46.2

Face Value₹10.0

Dividend Yield0.00%

About

Incorporated in 2004, Indo US Bio-Tech Ltd is engaged in production and processing of commercial and vegetable seeds[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	19.14	0.37	16.15	0.03	0.2	2.45	3.27	2.37	1.18
Sep 2023	15.81	0.41	13.21	0	0.21	1.98	15.66	1.67	0.83
Dec 2023	22.11	0.37	17.88	0.08	0.19	3.75	1.87	3.68	1.84
Mar 2024	15.77	0.36	14.79	0.21	0.2	0.63	17.46	0.52	0.26
Jun 2024	24.72	0.33	21.03	0.03	0.2	3.19	0.63	3.17	1.58
Sep 2024	22.17	0.52	17.05	0.02	0.18	4.44	2.03	4.36	2.17
Dec 2024	23.56	0.38	18.02	0.02	0.16	5.02	-0.8	5.05	2.52
Mar 2025	33.38	0.26	28.8	0.12	0.56	3.88	4.9	3.68	1.84
Jun 2025	30.77	0.45	25.3	0	0.2	4.82	2.49	4.7	2.34
Sep 2025	30.85	0.42	26.69	0.03	0.21	3.56	3.09	3.45	1.72
Dec 2025	22.8	0.77	18.65	0.01	0.22	3.17	5.36	3	1.5
Mar 2026	26.02	0.6	22.79	0.02	0.27	2.38	17.23	1.97	0.98
Jun 2026	32.99	0.74	29.02	0.12	0.27	3.08	1.3	3.04	1.52

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	20	0	19	0	0	-92	0	0.48
Mar 2016	19	0	19	0	0	-50	0	0.35
Mar 2017	24	1	23	0	1	25	0	0.38
Mar 2018	29	1	27	0	2	29	1	1.41
Mar 2019	35	0	32	0	3	26	2	1.44
Mar 2020	40	1	36	0	3	12	3	1.74
Mar 2021	39	1	34	0	4	-23	5	3.52
Mar 2022	49	1	42	0	5	5	5	2.86
Mar 2023	61	1	51	1	7	2	7	3.6
Mar 2024	73	2	62	1	9	6	8	4.11
Mar 2025	104	1	85	1	17	2	16	8.11
Mar 2026	110	2	93	1	14	6	13	6.54
TTM	113	3	97	1	12	—	11	5.72

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	68.29%
FIIs	0.01%
DIIs	0.25%
Public	31.46%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	70.17%	0%	0%	29.83%
Mar 2024	70.18%	0%	0%	29.83%
Jun 2024	70.18%	0%	0%	29.82%
Sep 2024	70.18%	0%	0%	29.83%
Dec 2024	70.18%	0%	0%	29.82%
Mar 2025	70.18%	0%	0%	29.83%
Jun 2025	70.18%	0%	0%	29.83%
Sep 2025	70.18%	0%	0%	29.83%
Dec 2025	70.18%	0%	0%	29.83%
Mar 2026	68.29%	0.18%	0%	31.53%
Jun 2026	68.29%	0.01%	0%	31.7%
Sep 2026	68.29%	0.01%	0.25%	31.46%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Other Assets	Total Assets
Mar 2015	1	1	2	3	8	1	0	7	8
Mar 2016	1	2	5	6	14	1	0	13	14
Mar 2017	1	2	5	4	13	1	0	11	13
Mar 2018	3	2	7	6	17	2	0	16	17
Mar 2019	5	9	6	4	24	1	1	21	24
Mar 2020	6	10	9	10	35	1	1	32	35
Mar 2021	6	15	11	11	44	2	2	39	44
Mar 2022	9	30	12	4	56	6	2	48	56
Mar 2023	10	44	12	3	69	7	1	61	69
Mar 2024	20	43	14	7	84	7	4	74	84
Mar 2025	20	58	15	4	98	10	0	88	98
Mar 2026	20	72	37	4	133	11	0	121	133

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	—	—	—	—
Mar 2016	—	—	—	—
Mar 2017	0	0	0	0
Mar 2018	-1	0	1	0
Mar 2019	-3	-3	6	0
Mar 2020	-1	-1	2	0
Mar 2021	0	-2	1	0
Mar 2022	3	-5	2	0
Mar 2023	1	-7	6	0
Mar 2024	2	-3	1	1
Mar 2025	1	-1	-1	-1
Mar 2026	-13	-2	20	6

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	25	107	76	112	94	193	229	152	148	95	53	45
Inventory Days	91	118	92	98	176	751	—	—	—	—	—	—
Days Payable	57	115	64	71	34	667	—	—	—	—	—	—
Cash Conversion Cycle	59	110	104	138	236	276	229	152	148	95	53	45
Working Capital Days	66	33	34	59	129	137	186	257	285	266	247	248
ROCE %	14%	7%	14%	28%	20%	17%	18%	16%	15%	14%	21%	14%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of INDO US BIOTECH LTD (INDOUS)?

The reported market capitalisation for INDO US BIOTECH LTD (INDOUS) is ₹144Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of INDOUS?

The current price shown for INDO US BIOTECH LTD (INDOUS) on Fincrux is ₹72.0 with a 52-week high/low of ₹159/70.0.

What is the P/E ratio of INDO US BIOTECH LTD (INDOUS)?

The stock P/E for INDO US BIOTECH LTD (INDOUS) is 12.6 on Fincrux, with ROE at 15.3% and ROCE at 14.5%.

What were INDOUS latest quarterly results?

For Jun 2026, INDO US BIOTECH LTD (INDOUS) reported sales ₹32.99 Cr and net profit ₹3.04 Cr (figures in ₹ crore unless noted).

What are INDOUS annual sales and net profit?

For TTM, INDO US BIOTECH LTD (INDOUS) shows sales of ₹113 Cr and net profit of ₹11 Cr on the Fincrux profit & loss statement.

Who owns INDO US BIOTECH LTD (INDOUS)?

Latest shareholding for INDO US BIOTECH LTD (INDOUS) on Fincrux: Promoters 68.29% (Sep 2026), FIIs 0.01% (Sep 2026), DIIs 0.25% (Sep 2026), Public 31.46% (Sep 2026), No. of Shareholders 4,629% (Sep 2026).

Where can I find INDO US BIOTECH LTD (INDOUS) financials?

INDO US BIOTECH LTD (INDOUS) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show INDOUS balance sheet and cash flow?

Yes. The INDO US BIOTECH LTD (INDOUS) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 13:03